Conditions: Alzheimer's Disease
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 40
Healthy volunteers: yes

Brief summary:
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.

Detailed description:
This is a Phase 1 study with 2 parts, both in healthy subjects. Part 1 is a subject- and investigator-blind, placebo-controlled, randomized, 3-period, crossover study. Part 1 will assess the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body. Part 2 is a subject- and investigator-blind, placebo-controlled, randomized study to assess the safety and tolerability of an LY2886721 single dose, how the body handles the drug, and the drug's effect on the body including in cerebrospinal fluid.

Arms:
arm 1: Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods arm 2: Single dose in up to 1 period arm 3: Single 10 mg dose of LY2886721, dose determined by Part 1 arm 4: Single 35 mg dose of LY2886721, dose determined by Part 1 arm 5: Single dose

Interventions: intervention 1: LY2886721 intervention 2: Placebo
Intervention descriptions: intervention 1: Oral capsules intervention 2: Oral capsules

Protocol document: